Protection by meningococcal group A, C, W and Y (MenACWY) vaccines against four
meningococcal disease-causing serogroups is increasingly important because of changing …

Background Invasive meningococcal disease has a high mortality rate in individuals aged≥
56 years, but no vaccine is currently licensed in the USA for this age group. This study …

Background The C5 complement inhibitor eculizumab is a first-line treatment in atypical
haemolytic uraemic syndrome (aHUS). Therapy with eculizumab is associated with a highly …

Conjugate vaccine platform is a promising strategy to overcome the poor immunogenicity of
bacterial polysaccharide antigens in infants and children. A carrier protein in conjugate …

Vaccine responsiveness is often reduced in older adults. Yet, our lack of understanding of
low vaccine responsiveness hampers the development of effective vaccination strategies to …

Neisseria meningitidis is often asymptomatically carried in the nasopharynx but may cause
invasive meningococcal disease, leading to morbidity and mortality. Meningococcal …

Live anthrax vaccine containing spores from attenuated strains STI-1 of Bacillus anthracis is
used in Russia and former CIS (Commonwealth of Independent States) to prevent anthrax …

Background We compared postinfection severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) neutralizing antibody (nAb) responses among children and adults while the …

Introduction Prevention of infectious diseases in the elderly is essential to establish healthy
aging. Yet, immunological aging impairs successful vaccination of the elderly. Predictive …

Introduction Successful vaccination of elderly persons is often hampered by immunological
ageing, leaving part of the elderly population vulnerable for infectious diseases. As an …